Comparative Pharmacology
Head-to-head clinical analysis: ETRAVIRINE versus INTELENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAVIRINE versus INTELENCE.
ETRAVIRINE vs INTELENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing allosteric inhibition of RNA-dependent and DNA-dependent DNA polymerase activities.
Non-nucleoside reverse transcriptase inhibitor (NNRTI). Binds directly to HIV-1 reverse transcriptase, causing allosteric inhibition of RNA-dependent and DNA-dependent DNA polymerase activities.
400 mg orally twice daily after meals.
200 mg orally twice daily after a meal.
None Documented
None Documented
Terminal elimination half-life approximately 41 hours (range 20-70 hours) following multiple doses; supports once-daily dosing with a pharmacokinetic booster (e.g., ritonavir or cobicistat).
Clinical Note
moderateEtravirine + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Etravirine."
Clinical Note
moderateEtravirine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Etravirine."
Clinical Note
moderateEtravirine + Cyclosporine
"The serum concentration of Cyclosporine can be increased when it is combined with Etravirine."
Clinical Note
moderateEtravirine + Fluconazole
Terminal elimination half-life is approximately 40 hours (range 30-60 hours). This supports once-daily dosing with 400 mg (two 200 mg tablets) after initial twice-daily dosing for 2 weeks, but note that etravirine is only approved for twice-daily dosing (200 mg twice daily) in treatment-experienced patients.
Fecal: ~93.7% (unchanged drug and metabolites; bile is the major route); Renal: ~1.2% (urinary, negligible unchanged drug).
Primarily fecal (76.6% as unchanged drug or metabolites) with minor renal excretion (19.6%, of which 1.2% is unchanged). Biliary elimination of metabolites may occur.
Category C
Category C
NNRTI Antiretroviral
NNRTI Antiretroviral
"The serum concentration of Fluconazole can be increased when it is combined with Etravirine."